Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy

Prime-boost vaccination employing heterologous viral vectors encoding an antigen is an effective strategy to maximize the antigen-specific immune response. Replication-deficient adenovirus serotype 5 (Ad5) is currently being evaluated clinically in North America as a prime in conjunction with oncoly...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Ther Oncolytics
Autori principali: Tzelepis, Fanny, Birdi, Harsimrat Kaur, Jirovec, Anna, Boscardin, Silvia, Tanese de Souza, Christiano, Hooshyar, Mohsen, Chen, Andrew, Sutherland, Keara, Parks, Robin J., Werier, Joel, Diallo, Jean-Simon
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Gene & Cell Therapy 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7658579/
https://ncbi.nlm.nih.gov/pubmed/33209979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.10.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi